Nexus Investment Management Inc. Has $21.82 Million Stake in Pfizer, Inc. (PFE)
Nexus Investment Management Inc. increased its stake in Pfizer, Inc. (NYSE:PFE) by 0.7% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 649,630 shares of the biopharmaceutical company’s stock after acquiring an additional 4,800 shares during the quarter. Pfizer accounts for approximately 3.6% of Nexus Investment Management Inc.’s portfolio, making the stock its 10th largest position. Nexus Investment Management Inc.’s holdings in Pfizer were worth $21,821,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in PFE. Fisher Asset Management LLC raised its stake in Pfizer by 1.7% during the 1st quarter. Fisher Asset Management LLC now owns 32,759,530 shares of the biopharmaceutical company’s stock worth $1,120,704,000 after buying an additional 554,777 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in Pfizer by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock worth $1,069,433,000 after acquiring an additional 377,404 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in Pfizer by 0.9% in the first quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock worth $844,431,000 after acquiring an additional 228,405 shares in the last quarter. Boston Partners boosted its holdings in Pfizer by 7.3% in the first quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after acquiring an additional 1,649,801 shares in the last quarter. Finally, Bank of Montreal Can boosted its holdings in Pfizer by 1.2% in the second quarter. Bank of Montreal Can now owns 18,534,159 shares of the biopharmaceutical company’s stock worth $622,562,000 after acquiring an additional 227,682 shares in the last quarter. Institutional investors own 69.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Marea Informative and is the property of of Marea Informative. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at http://www.mareainformativa.com/nexus-investment-management-inc-has-21-82-million-stake-in-pfizer-inc-pfe/115662/.
In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Laurie J. Olson sold 8,064 shares of the stock in a transaction on Monday, August 21st. The shares were sold at an average price of $32.70, for a total value of $263,692.80. Following the sale, the insider now owns 74,506 shares in the company, valued at $2,436,346.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is owned by company insiders.
PFE has been the subject of a number of research reports. Morgan Stanley reissued a “neutral” rating and issued a $35.00 price objective (down previously from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Jefferies Group LLC reaffirmed a “neutral” rating and set a $34.00 target price on shares of Pfizer in a research report on Friday, June 16th. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Cowen and Company set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a report on Monday, July 10th. Finally, Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a report on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $38.25.
Pfizer, Inc. (PFE) traded down 0.5152% during midday trading on Wednesday, hitting $35.9538. The stock had a trading volume of 4,501,919 shares. The firm has a market cap of $213.83 billion, a price-to-earnings ratio of 26.3012 and a beta of 1.00. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $36.24. The firm has a 50 day moving average of $34.48 and a 200 day moving average of $33.64. Pfizer also was the recipient of unusually large options trading activity on Monday. Stock investors purchased 24,211 call options on the stock. This represents an increase of approximately 129% compared to the typical daily volume of 10,577 call options.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.64 earnings per share. Equities research analysts predict that Pfizer, Inc. will post $2.56 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be issued a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.54%. Pfizer’s payout ratio is currently 94.12%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.